Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PHGDH | O43175 | 1/20 | 0.35 |
| ▸ | DPP4 | P27487 | 2/20 | 0.35 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.33 |
| ▸ | RECQL | P46063 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19528227 | 0.86 | PHGDH (0.41) | PHGDHDPP4RECQLMEN1ALDH1A1 | |
| SCHEMBL19658092 | 0.86 | PHGDH (0.41) | PHGDHDPP4RECQLMEN1ALDH1A1 | |
| SCHEMBL15038544 | 0.86 | PHGDH (0.41) | PHGDHDPP4RECQLMEN1ALDH1A1 | |
| SCHEMBL15033777 | 0.85 | PHGDH (0.35) | PHGDHDPP4PIK3CDRECQLMEN1 | |
| SCHEMBL21145954 | 0.83 | DPP4 (0.32) | PHGDHDPP4 | |
| SCHEMBL19658164 | 0.83 | DPP4 (0.37) | PHGDHDPP4 | |
| SCHEMBL20467016 | 0.81 | DPP4 (0.41) | PHGDHDPP4PIK3CDRECQLMEN1 | |
| SCHEMBL18994085 | 0.77 | PIK3CD (0.30) | PIK3CD | |
| SCHEMBL15033766 | 0.77 | DPP4 (0.31) | PHGDHDPP4 | |
| SCHEMBL15033795 | 0.77 | DPP4 (0.35) | PHGDHDPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10800789-B2 | Antiviral compounds | GILEAD PHARMASSET LLC (US) | 2020-10-13 | — | — | US | disclosed |
| US-10344019-B2 | Antiviral compounds | GILEAD PHARMASSET LLC (US) | 2019-07-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10344019-B2 | Antiviral compounds | MAVS, EIF2AK2, ZC3HAV1 | PHGDH 2018/4885DPP4 77/4885PIK3CD 1022/4885 |
| US-10800789-B2 | Antiviral compounds | MAVS, EIF2AK2, SARS1 | PHGDH 2273/4885DPP4 136/4885PIK3CD 785/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.